Evidence map›Paper›PMID 28294641›Full record

Trial reportJournal of medical economics2017

Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.

B Hunt, M Mocarski, W J Valentine, J Langer

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of medical economics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01952145. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01952145 phase3completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)

Ran2013Enrolled557Registered outcomes3Posted comparisons1ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec/liraglutide, Insulin glargine
PMID 26934259PMID 30383495PMID 28281218PMID 28643425PMID 28417535PMID 29276398other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin.Clinical diabetes : a publication of the American Diabetes Association · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

B Hunta Ossian Health Economics and Communications , Basel , Switzerland.
M Mocarskib Novo Nordisk Inc. , Plainsboro , NJ , USA.
W J Valentinea Ossian Health Economics and Communications , Basel , Switzerland.
J Langerc Novo Nordisk A/S , Søborg , Denmark.
Novo Nordisk (Denmark) · DKNovo Nordisk (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIDegLira, a fixed ratio combination of insulin degludec and glucagon-like peptide-1 receptor agonist liraglutide, utilizes the complementary mechanisms of action of these two agents to improve glycemic control with low risk of hypoglycemia and avoidance of weight gain. The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira vs liraglutide added to basal insulin, for patients with type 2 diabetes not achieving glycemic control on basal insulin in the US setting.

methodsProjections of lifetime costs and clinical outcomes were made using the IMS CORE Diabetes Model. Treatment effect data for patients receiving IDegLira and liraglutide added to basal insulin were modeled based on the outcomes of a published indirect comparison, as no head-to-head clinical trial data is currently available. Costs were accounted in 2015 US dollars ($) from a healthcare payer perspective.

resultsIDegLira was associated with small improvements in quality-adjusted life expectancy compared with liraglutide added to basal insulin (8.94 vs 8.91 discounted quality-adjusted life years [QALYs]). The key driver of improved clinical outcomes was the greater reduction in glycated hemoglobin associated with IDegLira. IDegLira was associated with mean costs savings of $17,687 over patient lifetimes vs liraglutide added to basal insulin, resulting from lower treatment costs and cost savings as a result of complications avoided.

conclusionsThe present long-term modeling analysis found that IDegLira was dominant vs liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the US, improving clinical outcomes and reducing direct costs.

Indexed as

Blood GlucoseBlood PressureBody Mass IndexCost-Benefit AnalysisDiabetes ComplicationsDiabetes Mellitus, Type 2Double-Blind MethodDrug CombinationsDrug Therapy, CombinationGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinInsulin, Long-ActingLipidsBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic AgentsIDegLiraInsulininsulin degludecInsulin, Long-ActingLipidsLiraglutideCostcost-effectivenessIDegLiraliraglutidetype 2 diabetes mellitusUSA

Identifiers

PMID28294641
OpenAlexW2612586128

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.